AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04705415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide is an antihelmintic with in-vitro antiviral activity
Study NCT04705415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
Study NCT02263456 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Replenine®-VF (High Purity Factor IX)
Study NCT02263456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replenine®-VF (High Purity Factor IX)
Study NCT04320511 — intervention group
Intervention type: DEVICE
Intervention: CT-V
Description: CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
Study NCT04138719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel + Carboplatin
Description: nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
Study NCT04138719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel + Epirubicin
Description: nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and epirubicin given IV at 75 mg/m\^2 on days 1 every 21 days x 6 cycles；
Study NCT01483209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of botulinum toxin A
Description: One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
Study NCT04738253 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: The ultrasound measurement s of the axillary recess capsule thickness.
Study NCT03266939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT04479644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-198
Description: BRII-198 given intravenously
Study NCT01827813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal prostate biopsy with ultrasonography.
Description: Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
Study NCT01827813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic block
Description: Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
Study NCT01827813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedoanalgesia
Description: Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
Study NCT04896203 — intervention group
Intervention type: PROCEDURE
Intervention: rotational thromboelastometry
Description: Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
Study NCT06244836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a bundle of care
Study NCT00914550 — intervention group
Intervention type: OTHER
Intervention: Procalcitonin level, caregiver informed
Description: Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
Study NCT05135234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscular Exercise
Description: Sedentary time (muscular inactivity when sitting) will be replaced with low effort muscular activity
Study NCT03403036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Weeks 0, 1, 2, and every 2 weeks thereafter through and including Week 16.
Study NCT04185818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading a book
Description: Participants requested to specify usual genre of book they read.~1. Fiction~2. Non-Fiction~3. Other~4. Don't usually read a book in bed
Study NCT01685983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
Study NCT01685983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
Study NCT00657371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Third Eye Retroscope Auxiliary Imaging System
Description: A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
Study NCT02916147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study NCT02916147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT00539422 — intervention group
Intervention type: GENETIC
Intervention: pcr and serum markers for breast cancer
Description: DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
Study NCT02768025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional & Complementary Medicine treatment
Description: Body acupuncture, Ear acupuncture and aromatic therapy
Study NCT02768025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NRT, counselling
Description: Nicotine Replacement Therapy, counselling
Study NCT02768025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NRT, counselling
Description: Nicotine Replacement Therapy, counselling
Study NCT03276949 — intervention group
Intervention type: DEVICE
Intervention: Blood glucose measurement
Description: Device used to measure blood glucose levels
Study NCT04401670 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HPV screening and triage tests
Description: The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt \[Hologic, Inc., Bedford, MA, USA\] and a visual inspection by acetic acid (VIA) by a nurse.
Study NCT04401670 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HPV self-sampling
Description: The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler \[Preventive Oncology International, Cleveland, OH, USA\].
Study NCT05239221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZP-3601
Description: Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
Study NCT05239221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution visually matching active medication
Study NCT02982499 — intervention group
Intervention type: DEVICE
Intervention: magnetic resonance image (MRI)
Description: Radiographic imaging that takes about 30-45 minutes
Study NCT02982499 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: Images taken from the back of the eye (retina)
Study NCT03770247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative celiac plexus neurolysis
Description: neurolysis of celiac plexus by intraoperative techniques
Study NCT03770247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT guided celiac plexus neurolysis
Description: Neurolysis of celiac plexus percutaneously by CT guidance
Study NCT02459860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment
Description: Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
Study NCT02459860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
Study NCT01653652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Study NCT01653652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT01815359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Optimal Surgical Debulking
Study NCT04479644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously
Study NCT01603381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: Behavioral management of insomnia
Study NCT01815359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC with Mitomycin-C
Study NCT02735538 — intervention group
Intervention type: PROCEDURE
Intervention: osteonecrosis of femoral head group
Description: The patients with osteonecrosis of femoral head will undergo total hip replacement.
Study NCT02735538 — intervention group
Intervention type: PROCEDURE
Intervention: osteoarthritis group
Description: The patients with osteoarthritis will undergo total hip replacement.
Study NCT00605553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules~Placebo for 7 days
Study NCT00605553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant
Description: 20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
Study NCT03026478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Dipropionate
Study NCT03026478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate
Study NCT03077698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Cridanimod
Description: The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
Study NCT02392949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive mobilization
Description: An anterior-posterior manual pressure act on the cervical spine of the subject
Study NCT03077698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progestin therapy
Description: The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
Study NCT02657564 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Polyethylene glycol (PEG)
Description: Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
Study NCT00023751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT02392949 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
Study NCT03511092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB-FA
Description: One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
Study NCT03511092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB-Ca
Description: One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
Study NCT00023751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00023751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00023751 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04346030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
Study NCT04346030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
Study NCT04346030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine hydrochloride
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
Study NCT04346030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine hydrochloride
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
Study NCT04346030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
Study NCT03107923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dobutamine stress test
Description: Test of myocardial reserve
Study NCT01829282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction
Study NCT01829282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Reduction
Study NCT00576030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hab cof with water
Description: habitual coffee drinker provided with water
Study NCT00576030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hab cof with dec espresso
Description: habitual coffee drinkers given decaffeinated espresso
Study NCT00576030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hab cof with caf espresso
Description: habitual coffee drinkers given caffeinated espresso
Study NCT00576030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-hab cof with water
Description: non-habitual coffee drinkers given water
Study NCT00576030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-hab cof with dec espresso
Description: non-habitual coffee drinkers given decaffeinated espresso
Study NCT03511092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alfa-HICA
Description: Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.
Study NCT03511092 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
Study NCT03883035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: automatic quality-control system
Description: Automatic quality-control system could real-time measuring endoscopic inspection completeness, detecting gastric neoplasms and evaluating gastric mucosal visibility.
Study NCT03458299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: 2 hours of motivational interviewing
Study NCT03458299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 2 hours of DVD viewing and discussion
Study NCT00400842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-001
Description: 0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days
Study NCT00400842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-001
Description: 0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days
Study NCT00400842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02533180 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Immunosuppression withdrawal
Description: Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.~CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.~Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.~If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued.
Study NCT01667328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Presurgical 15 minute massage performed by a licensed massage therapist
Study NCT01667328 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Control group will receive standard of care with no massage therapy
Study NCT02722915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: collection of functional brain data for 1 hour per day
Study NCT02722915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 \& 4; controls without AVH: Days 2 \& 3)
Study NCT02722915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PANAS
Description: to assess the mood before and after the fMRI and after 1 week during a telephone interview
Study NCT02722915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AVHRS
Description: to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
Study NCT00576030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-hab cof with caf espresso
Description: non-habitual coffee drinkers given caffeinated espresso
Study NCT00690287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6370
Description: Oral single doses a+b+c, o.d., suspension
Study NCT02722915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF36
Description: questionnaire about life quality after 1 week during a telephone interview
Study NCT01955083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillar implant
Description: Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.